Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Illumina, Inc. ILMN

Healthcare  —  Diagnostics & Research
270.00 (3.90) (1.42%) as of 25 Sep
Market cap
$41.3B
P/E
50.4×
S&P 500 Member Cash Flow Champion (3y) Insider Buys (last 12m)
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Illumina, Inc. (ILMN) Business Profile

Updated before January 2025

Company Overview

Illumina, Inc. (NASDAQ: ILMN) is a global leader in the field of genomics, specializing in the development, manufacturing, and marketing of life science tools and integrated systems for the analysis of genetic variation and function. Founded in April 1998 by David Walt, Larry Bock, John Stuelpnagel, Anthony Czarnik, and Mark Chee, the company is headquartered in San Diego, California. Illumina’s mission is to improve human health by unlocking the power of the genome. Over the years, the company has played a pivotal role in advancing genomic research, enabling breakthroughs in personalized medicine, agriculture, and disease prevention.

The company’s leadership team is spearheaded by Francis deSouza, who has served as the President and CEO since 2016. Under his guidance, Illumina has expanded its global footprint and diversified its product portfolio. Other key executives include Joydeep Goswami, Chief Strategy and Corporate Development Officer, and Sam Samad, Chief Financial Officer. Illumina’s commitment to innovation and excellence has positioned it as a trusted partner for researchers, healthcare providers, and biopharmaceutical companies worldwide.

Core Business Segments

Illumina operates through several core business segments, offering a wide range of products and services that cater to the needs of the genomics community. These segments include:

1. Sequencing Systems

Illumina’s sequencing systems are at the heart of its product portfolio. These systems enable researchers to perform high-throughput DNA and RNA sequencing, which is critical for understanding genetic variation and function. Key products in this category include:

  • NovaSeq Series: Designed for large-scale genomic projects, NovaSeq systems offer unparalleled throughput and scalability.
  • NextSeq Series: Ideal for medium-sized projects, NextSeq systems provide flexibility and high data quality.
  • MiSeq Series: A compact and cost-effective solution for smaller-scale sequencing projects.
  • iSeq 100 System: A benchtop sequencer designed for affordability and ease of use.

2. Consumables

Illumina offers a wide range of consumables, including reagents, flow cells, and sample preparation kits, which are essential for running sequencing systems. These consumables are tailored to meet the specific needs of different sequencing applications, such as whole-genome sequencing, targeted resequencing, and RNA sequencing.

3. Microarrays

Illumina’s microarray technology is widely used for genotyping, gene expression profiling, and epigenetic analysis. Key products in this category include:

  • Infinium Assay Kits: High-throughput genotyping solutions for large-scale studies.
  • BeadChips: Customizable microarrays for targeted genomic analysis.

4. Software and Informatics

To complement its hardware and consumables, Illumina provides advanced software solutions for data analysis and interpretation. These tools help researchers and clinicians make sense of complex genomic data. Notable offerings include:

  • BaseSpace Sequence Hub: A cloud-based platform for data management and analysis.
  • DRAGEN Bio-IT Platform: High-performance genomic analysis software for accelerated data processing.

5. Services

Illumina also offers a range of services, including genomic services, training, and support. These services are designed to help customers maximize the value of their investments in Illumina’s technologies.

Business Model

Illumina’s business model is built on a combination of hardware, consumables, software, and services. The company generates revenue through the sale of sequencing systems, which serve as a gateway to recurring revenue streams from consumables and software subscriptions. By offering a comprehensive ecosystem of products and services, Illumina ensures customer loyalty and long-term engagement.

The company also collaborates with academic institutions, healthcare providers, and biopharmaceutical companies to drive innovation and expand the applications of its technologies. Licensing agreements and partnerships further contribute to its revenue streams.

Strategic Direction

Illumina is focused on driving growth through innovation, market expansion, and strategic partnerships. Key elements of its strategic direction include:

  • Expanding Clinical Applications: Illumina aims to accelerate the adoption of genomics in clinical settings, particularly in areas like oncology, reproductive health, and rare disease diagnosis.
  • Sustainability Goals: The company is committed to reducing its environmental footprint by adopting sustainable practices in manufacturing and operations.
  • New Product Development: Illumina continues to invest in research and development to introduce next-generation sequencing technologies and expand its product portfolio.
  • Global Expansion: The company is actively expanding its presence in emerging markets to tap into new customer segments.

Competitive Landscape

Illumina operates in a highly competitive market, facing competition from both established players and emerging startups. Key competitors include:

  • Thermo Fisher Scientific: A major player in the life sciences industry, offering a wide range of genomic analysis tools.
  • Pacific Biosciences (PacBio): Known for its long-read sequencing technology, which complements Illumina’s short-read sequencing.
  • Oxford Nanopore Technologies: Specializes in portable and real-time sequencing solutions.
  • BGI Genomics: A Chinese company offering cost-effective sequencing services and technologies.

Despite the competition, Illumina maintains a strong market position due to its robust product portfolio, extensive customer base, and commitment to innovation.

Risk Factors

Illumina faces several risks that could impact its business operations and financial performance. Key risk factors include:

  • Market Dependence: A significant portion of Illumina’s revenue comes from the sale of sequencing systems and consumables. Any decline in demand for these products could adversely affect the company.
  • Supply Chain Disruptions: The company relies on a global supply chain for raw materials and components. Disruptions in the supply chain could lead to production delays and increased costs.
  • Regulatory Challenges: As a provider of genomic technologies, Illumina is subject to stringent regulatory requirements, which could impact its ability to bring new products to market.
  • Competition: The genomics market is highly competitive, with new entrants and technological advancements posing a constant threat.

Recent Developments

Illumina has been at the forefront of innovation, introducing new products and technologies to meet the evolving needs of its customers. Recent developments include:

  • Launch of NovaSeq X Series: In 2023, Illumina unveiled the NovaSeq X series, its most advanced sequencing system to date, offering higher throughput and lower costs.
  • Partnerships and Collaborations: The company has entered into strategic partnerships with leading healthcare providers and research institutions to expand the applications of its technologies.
  • Focus on Oncology: Illumina has made significant strides in oncology, launching new assays and solutions for cancer research and diagnostics.

Investment Considerations

Investors considering Illumina as a potential investment should weigh the following strengths and risks:

Strengths

  • Market leadership in the genomics industry.
  • Strong product portfolio and recurring revenue streams.
  • Commitment to innovation and R&D.
  • Expanding applications in clinical and research settings.

Risks

  • Dependence on a few key products for revenue.
  • Exposure to regulatory and competitive pressures.
  • Potential supply chain disruptions.

Conclusion

Illumina, Inc. is a pioneer in the genomics industry, offering cutting-edge technologies that enable groundbreaking research and clinical applications. With a strong market position, a robust product portfolio, and a commitment to innovation, the company is well-positioned for future growth. However, investors should carefully consider the risks associated with market dependence, competition, and regulatory challenges. Overall, Illumina remains a key player in the genomics revolution, driving advancements in personalized medicine and beyond.